Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors
Satheesh K. Sengodan, … , Subhajyoti De, Shyam K. Sharan
Satheesh K. Sengodan, … , Subhajyoti De, Shyam K. Sharan
Published January 25, 2024
Citation Information: J Clin Invest. 2024;134(7):e173718. https://doi.org/10.1172/JCI173718.
View: Text | PDF
Research Article Genetics

Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors

  • Text
  • PDF
Abstract

Loss of BRCA2 (breast cancer 2) is lethal for normal cells. Yet it remains poorly understood how, in BRCA2 mutation carriers, cells undergoing loss of heterozygosity overcome the lethality and undergo tissue-specific neoplastic transformation. Here, we identified mismatch repair gene mutL homolog 1 (MLH1) as a genetic interactor of BRCA2 whose overexpression supports the viability of Brca2-null cells. Mechanistically, we showed that MLH1 interacts with Flap endonuclease 1 (FEN1) and competes to process the RNA flaps of Okazaki fragments. Together, they restrained the DNA2 nuclease activity on the reversed forks of lagging strands, leading to replication fork (RF) stability in BRCA2-deficient cells. In these cells, MLH1 also attenuated R-loops, allowing the progression of stable RFs, which suppressed genomic instability and supported cell viability. We demonstrated the significance of their genetic interaction by the lethality of Brca2-mutant mice and inhibition of Brca2-deficient tumor growth in mice by Mlh1 loss. Furthermore, we described estrogen as inducing MLH1 expression through estrogen receptor α (ERα), which might explain why the majority of BRCA2 mutation carriers develop ER-positive breast cancer. Taken together, our findings reveal a role of MLH1 in relieving replicative stress and show how it may contribute to the establishment of BRCA2-deficient breast tumors.

Authors

Satheesh K. Sengodan, Xiaoju Hu, Vaishnavi Peddibhotla, Kuppusamy Balamurugan, Alexander Y. Mitrophanov, Lois McKennett, Suhas S. Kharat, Rahul Sanawar, Vinod Kumar Singh, Mary E. Albaugh, Sandra S. Burkett, Yongmei Zhao, Bao Tran, Tyler Malys, Esta Sterneck, Subhajyoti De, Shyam K. Sharan

×

Figure 2

MLH1 promotes RF speed/restart and protects stalled RF in BRCA2-deficient cells.

Options: View larger image (or click on image) Download as PowerPoint
MLH1 promotes RF speed/restart and protects stalled RF in BRCA2-deficien...
(A) Representative images of DNA fibers showing dual color track length in control and Mlh1-silenced Brca2KO/KO-r, Brca2cKO/KO-mi, and Brca2cKO/KO clones. Right panel shows quantitation of dual color track length (in μm) using ImageJ. (B) Representative images showing IdU/CldU tract ratios of Brca2KO/KO-r (n = 2) and Brca2cKO/KO-mi (n = 1) clones. BRCA2 variant BRCA2Y3308X (known to have RF degradation) was used as positive control. Replicating DNA was labeled with CldU and IdU, and RFs were stalled by HU treatment. Ratio is approximately 1 when RFs are protected, but when they are not stable, the ratio is significantly less than 1. Right panel shows quantitation of IdU/CldU ratios using ImageJ. (C) Representative images showing IdU/CldU tract ratios of control or Mlh1- (upper panel) and Msh2- or Mlh3-silenced (lower panel) Brca2KO/KO-r and Brca2cKO/KO-mi clones. Right panel shows quantitation of IdU/CldU tract ratios using ImageJ. Original magnification, ×63. (D) Immunoblot showing confirmation of MLH1 knockout in MEFs. β-Actin was used as an endogenous control. Right panel shows quantitation of IdU/CldU tract ratios of BRCA2-proficient Mlh1KO/+(n = 1 MEFs) and Mlh1KO/KO (n = 2 MEFs from independent animals) MEFs. (E) Quantitation of IdU/CldU tract ratios of control or Mlh1-silenced Brca2KO/KO-r mESCs under Hltf-, Smarcal1-, or Zranb3-silenced conditions. (F) Schematic representation of RF protection or degradation in MLH1-proficient/deficient cells. Each dot represents an individual fiber, and at least 150 fibers pooled from 3 biological replicates (>50 fibers per replicate) were used to generate superplots in A–E. Each replicate is color coded. Data are represented as means ± SEM. Data were analyzed by unpaired, 2-tailed Student’s t test (A–E) using the mean from 3 biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts